Abstract
The 8p11 myeloproliferative syndrome (EMS) also known as stem cell leukemia-lymphoma syndrome (SCLL) is associated with translocations that disrupt FGFR1. The resultant fusion proteins are constitutively active tyrosine kinases, and different FGFR1 fusions are associated with subtly different disease phenotypes. We report here a patient with a t(8;17)(p11;q23) and an unusual myelodysplastic/myeloproliferative disease (MDS/MPD) characterized by thrombocytopenia due to markedly reduced size and numbers of megakaryocytes, with elevated numbers of monocytes, eosinophils and basophils. A novel mRNA fusion between exon 32 of the myosin XVIIIA gene (MYO18A) at chromosome band 17q11 and exon 9 of FGFR1 was identified. Partial characterization of the genomic breakpoints in combination of bubble-PCR with fluoresence in situ hybridization revealed that the t(8;17) arose from a three-way translocation with breaks at 8p11, 17q11 and 17q23. MYO18A–FGFR1 is structurally similar to other fusion tyrosine kinases and is likely to be the causative transforming lesion in this unusual MDS/MPD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.
Macdonald D, Reiter A, Cross NC . The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002; 107: 101–107.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.
Cross NC, Reiter A . Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16: 1207–1212.
Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998; 92: 1735–1742.
Zhang JG, Goldman JM, Cross NC . Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. Br J Haematol 1995; 90: 138–146.
Sohal J, Chase A, Mould S, Corcoran M, Oscier D, Iqbal S et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer 2001; 32: 155–163.
Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001; 98: 3778–3783.
Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998; 18: 84–87.
Popovici C, Adelaide J, Ollendorff V, Chaffanet M, Guasch G, Jacrot M et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci USA 1998; 95: 5712–5717.
Smedley D, Hamoudi R, Clark J, Warren W, Abdul-Rauf M, Somers G et al. The t(8;13)(p11;q11–12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet 1998; 7: 637–642.
Popovici C, Zhang B, Gregoire MJ, Jonveaux P, Lafage-Pochitaloff M, Birnbaum D et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 1999; 93: 1381–1389.
Guasch G, Mack GJ, Popovici C, Dastugue N, Birnbaum D, Rattner JB et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 2000; 95: 1788–1796.
Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billstrom R, Isaksson M et al. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer 2001; 32: 302–310.
Pini M, Gottardi E, Scaravaglio P, Giugliano E, Libener R, Baraldi A et al. A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. Hematol J 2002; 3: 315–316.
Guasch G, Popovici C, Mugneret F, Chaffanet M, Pontarotti P, Birnbaum D et al. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood 2003; 101: 286–288.
Grand EK, Grand FH, Chase AJ, Ross FM, Corcoran M, Oscier DG et al. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2004; 40: 78–83.
Furusawa T, Ikawa S, Yanai N, Obinata M . Isolation of a novel PDZ-containing myosin from hematopoietic supportive bone marrow stromal cell lines. Biochem Biophys Res Commun 2000; 270: 67–75.
Mori K, Furusawa T, Okubo T, Inoue T, Ikawa S, Yanai N et al. Genome structure and differential expression of two isoforms of a novel PDZ-containing myosin (MysPDZ) (Myo18A). J Biochem (Tokyo) 2003; 133: 405–413.
Cross M, Csar XF, Wilson NJ, Manes G, Addona TA, Marks DC et al. A novel 110 kDa form of myosin XVIIIA (MysPDZ) is tyrosine-phosphorylated after colony-stimulating factor-1 receptor signalling. Biochem J 2004; 380 (Part 1): 243–253.
Anastasiadou E, Schwaller J . Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update. Curr Opin Hematol 2003; 10: 40–48.
Gilliland DG . Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002; 39 (Suppl 3): 6–11.
Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 14479–14484.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by the Competence Network ’Acute and chronic leukemias’, sponsored by the German Bundesministerium für Bildung und Forschung (Projektträger Gesundheitsforschung; DLR e.V.-01G19980/6), the European LeukemiaNet’ within the 6th European Community Framework Programme for Research and Technological Development and the Leukaemia Research Fund, United Kingdom.
Rights and permissions
About this article
Cite this article
Walz, C., Chase, A., Schoch, C. et al. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 19, 1005–1009 (2005). https://doi.org/10.1038/sj.leu.2403712
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403712
Keywords
This article is cited by
-
Identification of a novel HOOK3-FGFR1 fusion gene involved in activation of the NF-kappaB pathway
Cancer Cell International (2022)
-
Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11)
Molecular Cytogenetics (2017)
-
Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation
Annals of Hematology (2016)
-
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Apoptosis (2013)
-
Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders
Leukemia (2012)